Sector
PharmaceuticalsOpen
₹174.5Prev. Close
₹175.43Turnover(Lac.)
₹469.24Day's High
₹177.83Day's Low
₹172.8152 Week's High
₹240.752 Week's Low
₹117.35Book Value
₹45.65Face Value
₹2Mkt Cap (₹ Cr.)
4,427.93P/E
260.44EPS
0.68Divi. Yield
027 Aug 2024
12:00 AM
AGM
Announcement Date: 27 Aug, 2024
8 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 50.06 | 49.89 | 49.89 | 58.81 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,092.59 | 1,037.34 | 1,008.48 | 982.28 |
Net Worth | 1,142.65 | 1,087.23 | 1,058.37 | 1,041.09 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 265.45 | 227.33 | 106 | 90.71 |
yoy growth (%) | 16.77 | 114.45 | 16.85 | -77.01 |
Raw materials | -108.86 | -113.04 | -79.37 | -72.52 |
As % of sales | 41.01 | 49.72 | 74.87 | 79.94 |
Employee costs | -22.41 | -17.09 | -11.85 | -17.9 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 43.44 | 22.81 | 1.82 | -15.16 |
Depreciation | -9.12 | -8.95 | -3.66 | -3.25 |
Tax paid | -8.77 | -1.47 | -2.86 | 0 |
Working capital | 33.97 | -80.01 | -110.8 | 56.46 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.77 | 114.45 | 16.85 | -77.01 |
Op profit growth | 58.69 | -220.94 | -39.83 | -186.01 |
EBIT growth | 65.64 | 1,156.67 | -115.03 | -154.81 |
Net profit growth | 50.47 | -94.74 | -33,86,825 | -100.11 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.69 | 10.96 | 6.39 | 10.85 | 8.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,710.5 | 96 | 4,10,466.23 | 2,000.46 | 0.94 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,676.5 | 80.29 | 1,77,298.5 | 667 | 0.45 | 2,536 | 561.08 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,768.1 | 67.4 | 1,27,532.36 | 551 | 0.16 | 2,567 | 224.34 |
Cipla Ltd CIPLA | 1,574 | 24.61 | 1,27,140.04 | 1,303.13 | 1.02 | 4,501.66 | 397.39 |
Dr Reddys Laboratories Ltd DRREDDY | 1,299.8 | 15.74 | 1,08,499.8 | 2,961.2 | 0.61 | 7,788.7 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Executive & Non-Independent Director
Neeraj Bharadwaj
Non-Executive & Non-Independent Director
Gregory John Andrews
Non-Executive & Non-Independent Director
Fabian Kausche
Chairman & Independent Director
Kamal K Sharma
Non Executive & Independent Director
Milind Sarwate
Managing Director & Chief Executive Officer
N Rajaram
Non-Executive & Non-Independent Director
Hari Babu Bodepudi
Company Sec. & Compli. Officer
PHILLIP TROTT
Whole Time Director
Vedprakash Ragate
Non Executive & Independent Director
Revati Kasture
301 Dosti Pinnacle 3rd Floor,
Plot E7 Road No 22 Wagle Indl,
Maharashtra - 400604
Tel: 91-022-41114777
Website: http://www.sequent.in
Email: investors@sequent.in
19/20 Jaferbhoy Ind,
1st Floor Makwana Rd, Marol Naka,
Mumbai - 400 059
Tel: 91-022-28594060
Website: www.adriotcorporate.com
Email: info@adroitcorporate.com
Summary
Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself. The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on N...
Read More
Reports by Sequent Scientific Ltd
What is the Sequent Scientific Ltd share price today?
What is the Market Cap of Sequent Scientific Ltd?
What is the PE and PB ratio of Sequent Scientific Ltd?
What is the 52 Week High and Low of Sequent Scientific Ltd?
What is the CAGR of Sequent Scientific Ltd?
What is the shareholding pattern of Sequent Scientific Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
